http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Definium+Therapeutics%2C+++++++++++++++/26654076.html si-local-file:///var/storage/secattach/20260616/26654076.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Definium+Therapeutics%2C+++++++++++++++/26654076.html Tue, 16 Jun 2026 16:07:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Definium+Therapeutics%2C+++++++++++++++/26654076.html si-local-file:///var/storage/secattach/20260616/26654076.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Definium+Therapeutics%2C+++++++++++++++/26654076.html Tue, 16 Jun 2026 16:07:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+CRYSTAL+ROGER/26647860.html si-local-file:///var/storage/secattach/20260615/26647860.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+CRYSTAL+ROGER/26647860.html Mon, 15 Jun 2026 16:31:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+CRYSTAL+ROGER/26647860.html si-local-file:///var/storage/secattach/20260615/26647860.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+CRYSTAL+ROGER/26647860.html Mon, 15 Jun 2026 16:31:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Bruhn+Suzanne+Louise/26647833.html si-local-file:///var/storage/secattach/20260615/26647833.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Bruhn+Suzanne+Louise/26647833.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Bruhn+Suzanne+Louise/26647833.html si-local-file:///var/storage/secattach/20260615/26647833.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Bruhn+Suzanne+Louise/26647833.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Krebs+Andreas/26647843.html si-local-file:///var/storage/secattach/20260615/26647843.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Krebs+Andreas/26647843.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Krebs+Andreas/26647843.html si-local-file:///var/storage/secattach/20260615/26647843.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Krebs+Andreas/26647843.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Adsett+Roger/26647845.html si-local-file:///var/storage/secattach/20260615/26647845.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Adsett+Roger/26647845.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Adsett+Roger/26647845.html si-local-file:///var/storage/secattach/20260615/26647845.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Adsett+Roger/26647845.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Vallone+Carol+A/26647850.html si-local-file:///var/storage/secattach/20260615/26647850.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Vallone+Carol+A/26647850.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Vallone+Carol+A/26647850.html si-local-file:///var/storage/secattach/20260615/26647850.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+Vallone+Carol+A/26647850.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+GRYSKA+DAVID+W/26647857.html si-local-file:///var/storage/secattach/20260615/26647857.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+GRYSKA+DAVID+W/26647857.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+GRYSKA+DAVID+W/26647857.html si-local-file:///var/storage/secattach/20260615/26647857.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Definium+Therapeutics%2C++++For%3A+Jun+11++Filed+by%3A+GRYSKA+DAVID+W/26647857.html Mon, 15 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html Mon, 15 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html Mon, 15 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html Mon, 15 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26647151.html Mon, 15 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Definium+Therapeutics%2C++++For%3A+Jun+11/26641353.html si-local-file:///var/storage/secattach/20260612/26641353.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Definium+Therapeutics%2C++++For%3A+Jun+11/26641353.html Fri, 12 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Definium+Therapeutics%2C++++For%3A+Jun+11/26641353.html si-local-file:///var/storage/secattach/20260612/26641353.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Definium+Therapeutics%2C++++For%3A+Jun+11/26641353.html Fri, 12 Jun 2026 16:30:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of options to purchase an aggregate of 462,190 common shares of the Company (the "Options") with effective grant dates of May 18, 2026 and June 1, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html Mon, 01 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of options to purchase an aggregate of 462,190 common shares of the Company (the "Options") with effective grant dates of May 18, 2026 and June 1, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html Mon, 01 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of options to purchase an aggregate of 462,190 common shares of the Company (the "Options") with effective grant dates of May 18, 2026 and June 1, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html Mon, 01 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of options to purchase an aggregate of 462,190 common shares of the Company (the "Options") with effective grant dates of May 18, 2026 and June 1, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26583297.html Mon, 01 Jun 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26531284.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT. </p><p> Audio webcasts and replays of available presentations will be accessible on Definium’s <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.definiumtx.com%2Fnews-events%2Fir-calendar&amp;esheet=54539610&amp;newsitemid=20260521502258&amp;lan=en-US&amp;anchor=Investor+Relations&amp;index=1&amp;md5=9a0eae05a36b624d92d5880e07419e0e" shape="rect">Investor Relations</a> website for up to 90 days following each event. </p><p> <b>About Definium Therapeutics</b> </p><p> The mission of Definium Therapeutics is to http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26531284.html Thu, 21 May 2026 07:00:00 -0400 DFTX O.12458983